Loading clinical trials...
Loading clinical trials...
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OF...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Acorda Therapeutics
NCT01221948 · Idiopathic Parkinson's Disease
NCT05094011 · Idiopathic Parkinson's Disease
NCT02610231 · Idiopathic Parkinson's Disease
NCT01668407 · Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy
NCT03665493 · Idiopathic Parkinson's Disease
Acorda Site #5020
Scottsdale, Arizona
Acorda Site #5042
Fresno, California
Acorda Site #5064
Fullerton, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions